ap301
Peptideexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jun 12, 2023 (NCT07030595)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06933472 | Phase 3 | Jun 13, 2025 | Alebund Pharmaceuticals, Fortrea |
| NCT06100627 | Phase 1 | Dec 14, 2023 | Alebund Pty Ltd, Nucleus Network Ltd |
| NCT07030595 | Phase 3 | Jun 12, 2023 | Alebund Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alebund Pharmaceuticals | For profit | 2 | 2 | 1 | 2023 |
| Alebund Pty Ltd | For profit | 1 | 1 | 1 | 2023 |
| Fortrea | For profit | 1 | 0 | 1 | 2025 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1